Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.42 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24225035 | 0.86 | TGM2 (0.58) | HTTTGM2MAPK3MEN1KMT2A | |
| SCHEMBL21568082 | 0.82 | HTT (0.51) | HTTHPGDPPARGLMNAMEN1 | |
| SCHEMBL13849156 | 0.80 | ALDH1A1 (0.52) | HTTHPGDPPARGLMNAMEN1 | |
| SCHEMBL31162390 | 0.80 | TGM2 (0.58) | TGM2LMNAMAPK3MEN1KMT2A | |
| SCHEMBL21894170 | 0.80 | TGM2 (0.58) | TGM2LMNAMAPK3MEN1KMT2A | |
| SCHEMBL25463164 | 0.80 | HTT (0.42) | HTTHPGDPPARGEGFRLMNA | |
| SCHEMBL23293735 | 0.79 | TGM2 (0.47) | BTKTGM2LMNAMAPK3JAK3 | |
| SCHEMBL15828700 | 0.79 | KIF11 (0.51) | HTTHPGDPPARGLMNA | |
| SCHEMBL11508898 | 0.79 | TGM2 (0.61) | BTKTGM2EGFRLMNAJAK3 | |
| SCHEMBL16104950 | 0.78 | TGM2 (0.46) | BTKTGM2LMNAMAPK3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310453-A1 | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATING DIPEPTIDYL PEPTIDASE 1-MEDIATED CONDITIONS | INSMED INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-10 | — | — | US | disclosed |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11655221-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-20190247400-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING GRANULOMATOSIS WITH POLYANGIITIS | INSMED INCORPORATED | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | BTK 2905/4885HTT 4781/4885HPGD 679/4885 |
| US-11655221-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BTK 2905/4885HTT 4781/4885HPGD 679/4885 |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BTK 2907/4885HTT 4771/4885HPGD 669/4885 |
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPP3 | BTK 3126/4885HTT 4725/4885HPGD 710/4885 |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BTK 2907/4885HTT 4771/4885HPGD 669/4885 |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BTK 2905/4885HTT 4781/4885HPGD 679/4885 |
| US-20190247400-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING GRANULOMATOSIS WITH POLYANGIITIS | DPP7, DPP8, DPP9 | BTK 1305/4885HTT 4634/4885HPGD 2481/4885 |
| US-20230310453-A1 | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATING DIPEPTIDYL PEPTIDASE 1-MEDIATED CONDITIONS | PRSS3, SERPINB1, DPP3 | BTK 4202/4885HTT 4181/4885HPGD 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.